GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Proof of Concept Anti-ageing Clinical Study in Healthy Subjects
Not Applicable
Completed
- Conditions
- Skin Aging
- Interventions
- Other: Test product (Moisturising cream)Other: No treatmentOther: Positive control (Commercial market place moisturising cream)
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT03180645
- Locations
- 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany
A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)
Phase 2
Completed
- Conditions
- Hypertension, Pulmonary
- Interventions
- Drug: GSK2586881
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT03177603
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
To Assess the Cutaneous Irritation and Sensitization Potential of a Cosmetic Facial Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Participants
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Facial micellar cleanser
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 272
- Registration Number
- NCT03175562
- Locations
- 🇧🇷
GSK Investigational Site, Valinhos, Brazil
To Investigate the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleanser in Healthy Females With Sensitive Skin
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Micellar foaming cleanserOther: Micellar cleanser
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 122
- Registration Number
- NCT03172364
- Locations
- 🇧🇷
GSK Investigational Site, Campinas, São Paulo, Brazil
Accurate Recognition of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Airway Obstruction
- Interventions
- Other: Draft item setOther: Focus group interviewOther: Candidate item set
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 199
- Registration Number
- NCT03170999
- Locations
- 🇨🇳
GSK Investigational Site, Shenyang, China
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Danirixin 35 mg tabletsDrug: PlaceboDevice: Metered dose inhaler (MDI) sensor deviceDrug: Rescue medication
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT03170232
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03168438
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Patient Characteristics and Treatment Modalities in COPD Patients in China
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 848
- Registration Number
- NCT03161587
- Locations
- 🇨🇳
GSK Investigational Site, Zhengzhou, China
Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults
Phase 2
Completed
- Conditions
- Malaria
- Interventions
- Biological: RTS,S/AS01EBiological: RTS,S/AS01BProcedure: Sporozoite-infected mosquitoes challenge.
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 154
- Registration Number
- NCT03162614
- Locations
- 🇺🇸
GSK Investigational Site, Silver Spring, Maryland, United States
Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices
Not Applicable
Completed
- Conditions
- Extrinsic Dental StainOral Hygiene
- Interventions
- Other: Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)Other: Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silicaOther: Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80Other: Stannous fluoride (SnF2, 0.454%), RDA~120
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 220
- Registration Number
- NCT03160703
- Locations
- 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath